Table 3.
Univariable analysis | Multivariable analysis | |
---|---|---|
OR (95% CI) | Adjusted OR (95% CI) | |
Outcomes by Month 18 | ||
Allergen sensitization | 1.0 (0.5-1.8) | 1.1 (0.6-2.3) |
Eczema | 1.4 (0.8-2.2) | 1.4 (0.8-2.6) |
Rhinitis | 0.7 (0.4-1.4) | 0.7 (0.3-1.6) |
Early onset of wheeze and use of nebuliser/inhaler | 0.8 (0.3-1.7) | 0.6 (0.2-1.7) |
Outcomes by Month 36 | ||
Allergen sensitization | 0.9 (0.5-1.4) | 1.0 (0.5-1.9) |
Eczema | 1.2 (0.8-1.9) | 1.3 (0.7-2.4) |
Rhinitis | 1.0 (0.6-1.6) | 1.0 (0.6-1.8) |
Early onset of wheeze and use of nebuliser/inhaler | 0.7 (0.4-1.2) | 0.7 (0.3-1.4) |
Outcomes by Month 60 | ||
Allergen sensitization | 1.0 (0.7-1.6) | 1.1 (0.6-2.0) |
Eczema | 1.2 (0.8-1.9) | 1.3 (0.7-2.3) |
Rhinitis | 1.0 (0.6-1.6) | 1.0 (0.6-1.9) |
Early onset of wheeze and use of nebuliser/inhaler | 0.7 (0.4-1.2) | 0.6 (0.3-1.2) |
Adjusted for sex, ethnicity, breastfeeding levels, family history of allergy, gestational age, maternal education levels and mode of delivery